Aims: With evidence supporting the use of preventive interventions for prediabetes populations and the use of novel biomarkers to stratify the risk of progression, there is a need to evaluate their cost-effectiveness across jurisdictions. Our aim is to summarize and assess the quality and validity of decision models and model-based economic evaluations of populations with prediabetes, to evaluate their potential use for the assessment of novel prevention strategies and to discuss the knowledge gaps, challenges and opportunities. and 2018 for studies reporting computer simulation models of the natural history of individuals with prediabetes and/or we used decision models to evaluate the impact of treatment strategies on these populations. Data were extracted following PRISMA guidelines and assessed using modelling checklists. Two reviewers independently assessed 50% of the titles and abstracts to determine whether a full text review was needed. Of these, 10% was assessed by each reviewer to cross-reference the decision to proceed to full review. Using a standardized form and double extraction, each of four reviewers extracted 50% of the identified studies.
tolerance (IGT), are at high risk of developing diabetes. 3 In addition, individuals with prediabetes may face an increased risk of cardiovascular disease, early stage nephropathy, chronic kidney disease and diabetic retinopathy. 3 Lifestyle interventions in the form of diet and physical activity [4] [5] [6] [7] and/or pharmacological interventions 8, 9 have been shown to prevent or delay the onset of T2D in individuals with prediabetes. New developments concerning biomarkers for glycaemic deterioration potentially allow a more detailed stratification of the risk of developing diabetes, its progression and evaluation of novel treatments. [10] [11] [12] Such risk stratification strategies, based on biomarkers and clinical characteristics, could allow optimizing the management of individuals with prediabetes and diabetes based on expected treatment response, pharmacological or non-pharmacological, the likelihood of developing diabetes or complications and the potential for disease remission. 13, 14 As the number of preventive interventions for individuals with prediabetes grows, based on risk stratification or not, there is an increased need to assess whether the potential health gains justify the cost of implementation. Decision analysis models, based on computer simulations, are well suited to provide such evidence in the setting and time frame of interest to decision makers. 15 This is particularly relevant in prediabetes and diabetes, which develop over a long period of time. 1, 16, 17 Several models have been developed and validated for T2D populations and used in a variety of ways, such as estimating longterm clinical outcomes and costs of a clinical trial and aiding decision makers in choosing between available interventions in these populations. 16, [18] [19] [20] Similar to the situation with T2D, computer models of prediabetes populations must be clinically credible, based on the best available evidence, and must be reproducible and validated against clinical data. Furthermore, novel biomarkers and risk stratification introduce new requirements for these models, such as explicit modelling of screening and management of individuals at risk, simulating glycaemic deterioration trajectories over time and translating these trajectories into diabetes onset and progression. Evaluating novel diabetes-prevention programmes requires more comprehensive models capable of translating changes in several risk factors (eg, BMI, blood pressure) into lifetime costs and outcomes in a way that allows the possible inclusion of benefits broader than simply the prevention of diabetes itself (eg, heart disease, cancer). In addition, it must be ensured that the estimated prevention of cardiovascular and noncardiovascular events is not overestimated in these populations.
The aim of this systematic review was to summarize and assess the quality and validity of peer-reviewed and published decision models that simulate progression from prediabetes onset onwards and report health economics outcomes. We also evaluated the potential of these models to inform the evaluation of novel prevention strategies that use stratification and/or target more than one risk factor. Finally, we identified and discussed the research gaps to be addressed to inform future evaluations targeting prediabetes populations, based on computer models.
| MATERIALS AND METHODS
The protocol for the literature review was registered in the PROS-PERO international prospective register of systematic reviews (registration number CRD42016047228) and has been published elsewhere. 21 We did not deviate from the published protocol. No geography restrictions were applied to the search. Abstracts or conference presentations were not included as these are without sufficient data to allow critical appraisal of the decision models. The ref-
erence lists of the studies identified in the review were also searched, as well as those of previous literature reviews.
The inclusion criteria used to identify relevant studies were as follows:
• Studies with decision models of disease progression of prediabetes populations that reported health economics outcomes such as costs, (quality-adjusted) life expectancy and diabetes-related complications;
• Studies with model-based economic evaluations of intervention(s)
aimed at prediabetes populations such as cost-consequences, cost-utility, cost-effectiveness and cost-minimization studies.
Any recognized method of establishing prediabetes in an individual was considered, including, but not limited to, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), raised fasting plasma glucose or raised glycated haemoglobin (HbA1c). Studies concerning pre-existing diagnosis of diabetes were excluded as well as studies in gestational diabetes or mature onset diabetes of the young (MODY).
Economic evaluations that reported solely short-term outcomes such as incidence of type 2 diabetes and/or cases detected and costs following screening/detection were excluded.
References were managed using ENDNOTE X7, Thomson
Reuters. Duplicates were removed by one reviewer, after which two reviewers independently assessed 50% of the titles and abstracts to determine whether a full text review was necessary. A further 10%
was assessed by each reviewer to cross-reference the decision to proceed to full review. Any disagreement between the two reviewers was resolved by inclusion of a third reviewer for assessment.
Data extraction was performed using a standardised form (Appendix S3). If a decision model was found to be associated with multiple publications, data were extracted from the study that described the model in greater detail, the model supported by other publications and online documentation that was judged to be relevant.
Four reviewers each extracted 50% of the identified studies, with each study seen by two reviewers. Any disagreements were resolved by consensus.
The main outcomes analysed were: 1) prediabetes definition used; 2) model structure and rationale; 3) incorporation of individual heterogeneity; 4) hierarchy of evidence informing baseline clinical data, primary effect size and duration of primary effect, resource use, costs and quality of life/utilities; 5) model uncertainty and validation.
We used a hierarchy of evidence developed for economic analyses in which the data source used to inform a certain aspect of the model is awarded a score of one (highest quality) to six (lowest quality, expert opinion). 23 See "Data Details" in the Data Extraction form for full definitions of the hierarchy scale and respective rank (Appendix S3).
Two reviewers independently performed a quality appraisal of the studies. The Philips et al. 24 checklist was used to assess the quality of reporting of the decision models and model-based economic evaluations, as recommended in the Cochrane Handbook for Systematic
Reviews of Interventions. 25 The AdViSHE (A Validation-Assessment
Tool of Health-Economic Models for Decision Makers and Model Users) 26 checklist was used to assess model validation. The AdViSHE checklist was developed to support structured reporting of the model validation efforts performed and to increase model transparency. For the current review, it was used as a checklist to determine which aspects of model validity were reported in the publications. Disagreements were resolved by consensus and arbitration by a third reviewer.
We had problems in consistently scoring the Phillips checklist, given the potential interpretations of its 57 items and we needed additional rounds of consensus seeking to reach the final agreement. Findings from the review were synthesised in a narrative format.
This systematic review is exempt from ethics approval and consent of participants because the work was carried out with published documents.
| RESULTS
A total of 29 studies were identified that reported decision models simulating prediabetes populations from at least the onset of prediabetes onwards. Figure 1 shows the flow of studies throughout the review. An overview of each model is outlined in Table 1 , sorted by year of publication. Models were set in the USA (n = 6, 21%), 29, 30, 32, 42, 44, 50 the UK (n = 3, 10%), 35, 51, 52 Australia (n = 3, 10%), 34, 37, 46 other European countries (n = 7, 24%), 33, 36, 39, 41, 43, 47, 54 the Americas (n = 3, 10%), 27, 38, 45 Asia (n = 5, 17%) 40, 48, 49, 53, 55 and in multiple countries (n = 2, 7%). 28, 31 The type of intervention evaluated included screening programmes (n = 3, 10%), interventions (lifestyle and/or pharmacological) (n = 8, 28%), screening plus intervention (n = 17, 59%) and current care only (n = 1, 3%) (more detail in Appendix S2; Supporting Information 
| Definitions of prediabetes
A total of 21 studies (72%) defined prediabetes using blood glucose measurement criteria (n = 17) from the American Diabetes Association (ADA) (n = 7), the World Health Organisation (n = 5), the Diabetes Prevention Programme (DPP) Trial (n = 4), the UK National
Institute for Health and Care Excellence (n = 1) or using blood glucose values and other risk factors (n = 4) ( Table 1 and Appendix S2;
Supporting Information Table SA developed new T2D model structures but reported these to be based on previous T2D models, such as Eastman 1997. 56 The remaining studies reported an apparently new model structure, with the aim of addressing their particular research question. Complexity of the model structure varied across studies. Table 2 reports the health states explicitly included in the models. All models simulated progression from prediabetes to T2D and could be categorized into six types of model structure according to the health states included (Table 2 and Appendix S2; Supporting Information Figure SA .2). These categories ranged from relatively simple threestate models (n = 2), with prediabetes, diabetes and death, to comprehensive models that also included NGT and complications in nondiabetes/prediabetes and diabetes states (n = 7).
| Model structure
Modelling of the disease pathway also varied greatly, with 18 (62%) of the 29 models including a screening component and/or screening costs, 12 (41%) models allowing the individual to regress from prediabetes to normal glucose tolerance (NGT), four models (14%) allowing individuals with T2D to return to prediabetes, and two models (7%) allowing direct progression from NGT to T2D. In models with a screening component, individuals were mass screened for IGT, IFG or elevated HbA1c (n = 4), or were stratified before screening (eg, by age, BMI, diabetes risk score) (n = 11) (Appendix S2; Supporting Information 
.4). A minority of models allowed the individual to develop
complications in a prediabetes state (n = 8, 28%), which were mostly cardiovascular (eg, myocardial infarction, ischaemic heart disease, stroke, heart failure). Two models (Bertram 2010 and Breeze 2016) simulated explicitly the risk of major cardiovascular events (ischaemic heart disease, stroke, heart failure) in non-prediabetes and non-T2D However, the number and type of complications varied across models as did the sources used to inform the risk of such events (eg, Framingham Heart Study, UKPDS Risk Engine, UKPDS outcomes model, QRISK2, previous decision models, etc.). 
| Incorporation of risk factors, novel biomarkers and individual heterogeneity
Seven of the 29 models simulated annual changes in risk factors such as glycaemia (HbA1c, FPG, and/or 2-hr glucose), blood pressure (systolic and/or diastolic), BMI and lipids (total cholesterol and/or HDL) as individuals progressed in the model (see Table 2 and Appendix S2;
Supporting Information Table SA and BMI. The remaining two studies (Bertram 2010 and Liu 2013) explored heterogeneity by varying the risk of progression to T2D by age group and sex.
| Hierarchy of evidence informing models
Data from a range of studies were used to inform the prediabetes models. Table 2 shows that a minority of studies (n = 4) outlined a systematic method in which data were identified. The hierarchy of evidence used in the models is summarized in Figure 2 , ranging from high quality (rank 1: eg, meta-analysis or single RCT with direct comparison between comparator therapies for effect size) to low quality (rank 6: expert opinion). 
| Model validation
According to the AdViSHE checklist, 26 
| Model quality
According to the checklist from Philips et al., 24 the percentage of criteria fulfilled were unequally distributed across studies and dimensions of quality (model structure, model data and model consistency). 
| DISCUSSION
Given the high cost and burden of diabetes, there is significant interest in identifying strategies that prevent or delay the disease and that Yes No NA FIGURE 3 Quality of modelling studies according to the Philips checklist. Legend: A "yes" answer was assigned if a criterion was fulfilled. A "no" answer was assigned to criteria that were not fulfilled. NA indicates not applicable are cost-effective. Economic decision models simulating disease progression from normal glucose tolerance throughout the period of prediabetes to diabetes and its complications may support the economic evaluation of various screening and prevention strategies. Such computer models enable extrapolation from short-term empirical studies to predict health benefits and cost consequences over the lifetime of an individual. However, in order to assess stratified prevention strategies, such models should have a scope wide enough to capture the identification of individuals, their management and their response to treatment. Also, they should allow individual heterogeneity in risk of progression, according to biomarkers levels and their changes over time, to be taken into account. Furthermore, prediabetes models should consider all relevant outcomes, including onset of relevant comorbidities, in addition to the onset of T2D.
Our review identified 29 studies that use decision models to predict the progression of prediabetes and to evaluate prevention strate-
gies. An assessment of these studies indicates considerable limitations in current models in terms of their quality and validity. Furthermore, their potential to evaluate the impact of novel biomarkers, and of stratified prevention strategies using such biomarkers, seems limited, despite the growing evidence base linking biomarkers to prediabetes disease progression. [10] [11] [12] We found that the definitions of prediabetes varied considerably across the 29 models. Some models defined prediabetes as IGT, others as IFG, or both. Furthermore, studies used different glycaemic threshold values to define these states. The variation seemed to be largely a function of the clinical studies used to inform the model and their inclusion criteria, as well as changes in the classification and diagnosis of (pre)diabetes over time. This is relevant, as disease progression will differ according to the definition of prediabetes. 56 For example, IFG and IGT are considered distinct pathophysiological mechanisms and may lead to differing risks of developing diabetes or complications. 3 Thus, there is a need for agreement and standardization concerning the way prediabetes is defined in these models. This will also allow a better understanding of their findings, facilitate comparisons across models and allow transparent assessments of their validity. With increasing attention being given to heterogeneity among individuals with diabetes, heterogeneity in prediabetes may also require attention and current definitions may need to allow for larger variety in prediabetes subtypes. 57 The complexity of risk prediction models for diabetes incidence and the variety of covariates used 58, 59 were in stark contrast with the assumption, made in the majority of models, that the rate of progression to T2D was constant across the entire prediabetes population.
Furthermore, several well-validated T2D computer models allow prediction of many types of diabetes complications (eg, MI, stroke, heart failure, ischaemic heart disease, renal failure, blindness, etc.), 19 as well as second events, 16, 18, 20 conditional on baseline and/or time variant risk factors (eg, age, sex, cholesterol levels, HbA1c, history of complications, physical activity, etc.). However, the models identified in this review did not share the same complexity, and either simulated complications as a whole or simulated fewer complications, or simply did not simulate any complications. This is probably due, in part, to challenges in identifying suitable input data sources for prediabetes populations, as this requires a representative cohort that has been appropriately tested for prediabetes. While a diabetes cohort can be relatively easily recruited from diagnosed patients, a prediabetes cohort inevitably requires some form of screening and a longer follow up sufficient to identify the onset of diabetes and/or any subsequent complications.
Changes in glycaemia, blood pressure, BMI and/or lipids were simulated in seven models, but no other biomarkers were identified in our review. In terms of glycaemic deterioration, only three models simulated trajectories of HbA1c in the non-diabetes/prediabetes populations and based these on different methods and data sources.
However, these models allowed for a discontinuity in disease progression before and after diagnosis by simulating HbA1c deterioration after diabetes diagnosis, using risk factors and populations other than We found that normal glycaemia, prediabetes and T2D were largely handled as discrete events in the models. Although this was a convenient simplification of reality, it fails to model glycaemia deterioration as a continuum of risk and to account for the differing risk levels of disease progression among individuals with plasma glucose readings towards the upper limit of the normal range. 60 Also, with models informed by a variety of data sources and populations, it may introduce bias in terms of rates of disease progression when these are dependent on the study and the population informing the model rather than on the stage of disease. For example, models predicted vascular events using risk equations from T2D-only populations (eg, UKPDS Risk Engine and UKPDS Outcomes Model) together with equations from populations with subgroups of individuals with diabetes (eg, Framingham Heart Study or QRISK2) depending on whether the individuals had progressed to T2D. Furthermore, even for models using the same data source (eg, UKPDS Risk Engine or Framingham Heart Study) to predict vascular events, validity is likely to vary across non-diabetes and diabetes populations, 61 and we did not identify a model that used the same data source to inform disease progression during both prediabetes and T2D.
All interventions under evaluation in the models discussed in this review required identification of individuals with prediabetes within the general population. However, several models did not include or account for identification strategies. This is another necessary layer of complexity in prediabetes models; in particular, if the usefulness of novel biomarkers is to be evaluated, the screening and identification of individuals at risk must be accounted for. 65 also utilized an ISPOR checklist 67 to evaluate the relevance and credibility of results for policy makers. Our review contributes to existing reviews as it focuses on the health economic decision models.
It uses recognized modelling checklists, 24, 26 to provide a formal assessment of the models used to inform decision making in the prevention of diabetes. Concerning strengths and limitations, this is the first systematic review to critically assess the quality and validation of existing prediabetes models. It highlights that current prediabetes models have considerable limitations and may not be suitable to evaluate novel interventions such as those derived from the discovery of new biomarkers, an area of research that is receiving increased attention. This review has a number of limitations. First, risk prediction models for diabetes incidence and budget impact models were excluded from the review. Prediction models could have provided insights into the variables that are relevant to economic models that aim to evaluate novel biomarker strategies, 58 whereas budget impact models could have made apparent the variables relevant to assessment of financial impact. However, the aims of such models differ from the evaluation of novel prevention strategies and require different extraction forms, as well as quality and validation checklists. Second, only studies published in English were included in this review. Third, there may be a degree of publication bias as models that show an intervention to be cost-effective may be more likely to be published. Finally, the assessment of study quality may be biased as some studies were not described in full detail because of word count constraints; however, in the current era of online appendices, this bias should be less relevant.
Findings from this review have identified the need for validation of existing prediabetes models and for the development of more comprehensive models to more accurately evaluate novel biomarkerbased stratified interventions. Furthermore, use of the Philips checklist demonstrated the lack of quality data being used in current prediabetes models. Future research can focus on gathering high-quality data in order to build a more robust decision model.
To conclude, novel biomarkers have the potential to identify costeffective strategies that aim to prevent or delay the disease. Current prediabetes decision models have considerable limitations in terms of quality and validity, and they are not equipped to evaluate novel biomarkers for glycaemic deterioration, highlighting the clear need for the development of more comprehensive prediabetes decision models.
